fibrosis | GenomeWeb

fibrosis

This Week in PNAS

In PNAS this week: computational approach for finding heterotic patterns in hybrid wheat, single-cell RNA-seq study of fetal brain development, and more.

Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.

NEW YORK (GenomeWeb News) – Molecular imaging firm Edinburgh Molecular Imaging has received £4 million ($6.5 million) in a Series A investment, life science capital venture fund Epidarex Capital announced today.

Regulus Therapeutics remains on track to filing an investigational new drug application for its microRNA-targeting hepatitis C treatment RG-101 next year, with a second candidate — likely for fibrosis or cancer — to be added to the company's formal pipeline before the end of 2013

Roughly three years after partnering with Quark Pharmaceuticals to develop siRNA-based treatments for fibrotic diseases, Japan’s Nitto Denko has initiated its first clinical trial of an RNAi drug.

The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with GlaxoSmithKline for the use of KineMed's biomarker discovery platform in therapeutic areas of interest for the drug manufacturer.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Epistem today announced a research collaboration with GlaxoSmithKline to use its amplification technology to gain a better understanding of fibrosis.

The deal gives Sanofi worldwide, exclusive rights to use Regulus' technology and know-how to discover, develop, and sell four miRNA drugs.

NIDDK will fund small business grants for diagnostics, biomarkers, and other technologies for liver problems.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.